...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: Roth research report

Interesting.

I bought ACST immediately after the Amarin data was reported. The value proposition seemed impressive.

Can you expand on why you think ACST will have better data than Amarin?

I’m eager to see the hard 3 point MACE data for Vascepa.

 

bfw

Share
New Message
Please login to post a reply